South Carolina · Q5111

Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg in South Carolina

South Carolina Medicare Avg
$109.10
1% above national avg
National Medicare Avg
$107.77
All states combined
Billed Charge (SC)
$847.17
What providers submit
Est. Commercial (SC)
$321.79
National avg: $303.79
Est. Cash / Self-Pay (SC)
$335.67
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

1.1K
Services in SC
12
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in South Carolina

Provider Medicare Services
Sinclair, Pamela MD $108.58 456
Muslimani, Alaa MD $108.39 444

South Carolina Pricing in Context

In South Carolina, CPT code Q5111 (Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg) carries an average Medicare payment of $109.10 — 1% above the national benchmark of $107.77. 12 providers across the state submitted claims for this procedure in 2023, performing 1.1K total services. Individual payments in SC ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in South Carolina is $847.17, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because South Carolina sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Codes procedures, the estimated commercial insurance price in South Carolina lands near $321.79, with self-pay cash prices typically around $335.67. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg cost in South Carolina?

The average Medicare payment for Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg in South Carolina is $109.10, which is 1% above the national average of $107.77. Providers in SC typically bill $847.17 for this procedure.

What does Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg cost with insurance in South Carolina?

With commercial insurance in South Carolina, Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg costs an estimated $321.79. Without insurance, the estimated cash price is $335.67. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg in South Carolina?

12 providers in South Carolina billed Medicare for Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg in 2023, performing 1.1K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg cheaper in South Carolina than the national average?

No — Injection, Pegfilgrastim-Cbqv (udenyca), Biosimilar, 0.5 Mg costs 1% above the national average in South Carolina. The state average Medicare payment is $109.10 compared to $107.77 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial